Please try another search
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, Taiwan, and internationally. The company offers small molecular drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, the company develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Chih-Hsien Lo | 64 | 2010 | Chairman & General Chief Strategy Officer |
Wei-Te Ho | - | 2012 | Independent Director |
Shiow-Ling Kao | - | 2010 | Representative Director |
Tsung-Ming Su | 64 | 2010 | Representative Director |
Chiou-Ru Shih | - | 2010 | Representative Director |
Tsung-Pin Wu | - | 2015 | Representative Director |
Wen-Chang Chang | - | 2018 | Independent Director |
Lewis Lee | - | 2021 | Independent Director |
Po-Ming Hou | - | 2016 | Representative Director |
Jia-Horng Guo | - | 2017 | Representative Director |
Fu-Jung Lai | - | 2018 | Representative Director |
Li-Tzong Chen | - | 2018 | Independent Director |
Ya-Po Yang | 59 | 2018 | Representative Director |
Chin-Yuan Cheng | - | 2021 | Representative Director |
Ming-Chuan Hsieh | - | 2018 | Representative Director |
Chyun-Yu Yang | - | 2023 | Independent Director |
Ling-Ming Sun | - | 2023 | Representative Director |
Jang-Yang Chang | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review